Sarissa Capital urges Alkermes shareholders to vote for its board nominees after years of rejections

Sarissa Capital urges Alkermes shareholders to vote for its board nominees after years of rejections

Source: 
Fierce Pharma
snippet: 

After overhauling Amarin’s board earlier this year, activist investor Sarissa Capital has set its sights on Alkermes.

In a new letter to shareholders, the group is pressing Alkermes investors to vote for Sarissa’s board nominees and to vote against the company's planned compensation packages.